A STUDY OF PHARMACOKINETICS, EFFICACY, SAFETY, TOLERABILITY, OF THE COMBINATION OF SIMEPREVIR (TMC435), DACLATASVIR (BMS-790052), AND RIBAVIRIN (RBV) IN PATIENTS WITH RECURRENT CHRONIC HEPATITIS C GENOTYPE 1B INFECTION AFTER ORTHOTOPIC LIVER TRANSPLANTATION: